Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease

Abstract We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) eyes with age-related choroidal neovascularization (CNV) including neovascular macular degeneration, pachychoroid neovasculopathy, and polypoidal neovasculopathy. measured concentrations of activation products (C3a, C4a), VEGF, monocyte chemotactic protein-1 aqueous humor during intravitreal anti-VEGF injections for CNV. The VEGF level decreased significantly ( P < 0.001), while C3a C4a levels increased 0.001 both comparisons) 1 month after two monthly injections. was correlated (R = 0.328, 0.007) − 0.237, 0.055) at baseline, but correlation between 0.148, 0.242) changed 0.028 by analysis covariance) treatment. increase therapy did not change visual outcomes CNV year. Dysregulation can be induced therapy.